Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly executive Edgardo Hernandez reported an equity award of company stock. On 02/09/2026, he acquired 4,383.734 shares of Eli Lilly common stock in a grant or award at $1,044.67 per share. Following this award, he directly holds 46,095.717 shares and indirectly holds 871.35 shares through a 401(k) plan.
Eli Lilly and Company executive Anat Hakim, EVP, GC & Secretary, reported an acquisition of common stock through a grant or award. On 02/09/2026, she acquired 8,277.919 shares of Eli Lilly common stock at $1,044.67 per share, bringing her directly held stake to 22,987.024 shares.
The filing also notes indirect holdings of 15,700 shares held by the Anat Hakim SLAT and 16,875 shares held by her spouse, with a disclaimer that she disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
Eli Lilly & Co
Eli Lilly executive Kenneth L. Custer reported an equity award of company stock. On 02/09/2026, he acquired 659.28 shares of Eli Lilly common stock as a grant or award at a value of $1,044.67 per share. Following this non‑open‑market acquisition, he directly holds 10,024.855 Eli Lilly shares.
Eli Lilly and Company executive Adrienne S. Brown reported an acquisition of company stock. On February 9, 2026, the EVP, President LLY Imm received a grant or award of 1,196.308 shares of Eli Lilly common stock at $1,044.67 per share. Following this award, Brown directly beneficially owned 4,921.308 shares of Eli Lilly common stock.
Eli Lilly and Company filed a current report to furnish its financial results for the quarter and year ended December 31, 2025. The results themselves are provided in a separate press release attached as Exhibit 99.1, dated February 4, 2026.
The company states that the information in this report, including Exhibit 99.1, is being furnished under the securities laws and is not deemed filed or subject to certain liability provisions, unless specifically incorporated by reference in other documents.
Eli Lilly executive Ilya Yuffa reported equity compensation activity involving company stock. On February 1, 2026, 3,394 restricted stock units converted into an equal number of Eli Lilly common shares at an exercise price of $0, reflecting a standard vesting event.
On the same date, 1,512.364 shares of common stock were disposed of at $1,037.15 per share in a transaction coded “F,” indicating shares withheld to cover taxes related to the vesting. After these transactions, Yuffa directly owned 28,141.607 Eli Lilly common shares.
Eli Lilly EVP Daniel Skovronsky reported equity transactions on February 1, 2026. He exercised 12,684 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.
To cover related obligations, 5,641.249 common shares were withheld at a price of $1,037.15 per share. After these transactions, he directly holds 144,523.863 Eli Lilly common shares, with additional indirect holdings of 72,359 shares by a trust, 547 shares by his spouse, and 2,710 shares by his spouse's SLAT. He disclaims beneficial ownership of these reported securities except to the extent of his pecuniary interest.
Eli Lilly executive Jacob Van Naarden, EVP and President of LLY Oncology & Head of Corporate Business Development, reported equity movements in Eli Lilly common stock. On February 1, 2026, 4,108 restricted stock units were converted into the same number of common shares at an exercise price of $0, bringing his directly held common stock to 24,669.985 shares.
On the same date, 1,909.375 shares of common stock were withheld at a price of $1,037.15 per share, typically for tax obligations, leaving him with 22,760.61 shares of Eli Lilly common stock held directly. Separately, 4,342 shares are held indirectly through the Van Naarden Family Trust and 4,302 shares are held indirectly by his spouse. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Eli Lilly President, Chair, and CEO David A. Ricks reported equity award activity involving company stock on February 1, 2026. He exercised 31,932 restricted stock units, receiving the same number of Eli Lilly common shares at an exercise price of $0 per share.
On the same date, he disposed of 14,296.654 common shares at $1,037.15 per share, leaving 532,801.513 common shares held directly after the reported transactions. Additional indirect holdings are reported through several trusts, GRATs, a SLAT, and a 401(k) plan, with beneficial ownership disclaimed except to the extent of his pecuniary interest.